← 홈

프로그램 비교

타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일

현재 선택: 1개 · 임상 갱신 필요 1개

프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.

프로그램 선택

API CSV15행 · 1개 프로그램
OverviewToxicologyClinical

표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.

항목
AntibodyLimited DatastalePhase 1
acapatamab (acapatamab)
Amgen·Metastatic Castration-resistant Pr…
2 trials
Overview
Program
acapatamab
Overview
Company
Amgen
Overview
Modality
ANTIBODY
Overview
Target
Metastatic Castration-resistant Prostate
Overview
Indication
Metastatic Castration-resistant Prostate Cancer; Prostate Cancer
Overview
Phase
PHASE_1
Overview
Status
DISCONTINUED
Overview
Content status
Limited Data
Overview
Data Confidence
Data Confidence · Low
Overview
Development Signal
Development Signal · Watch
Overview
Approval status
Investigational
Toxicology
Major finding
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.. Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC refractory to androg…
Toxicology
CRS
97.4%
Clinical
Safety signal
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer.. Safety and efficacy of acapatamab, a prostate-specific membrane antigen (PSMA) x CD3 bispecific T-cell engager were evaluated in a first-in-human study in metastatic castration-resistant prostate cancer (mCRPC). Patients with mCRPC refractory to androg…
Clinical
Program phase
PHASE_1